PegBio Co., Ltd. Class H
3.40
HKD
-0.28
(-7.73%)
ISIN
CNE100006T44
Return %
Stock
S&P 500
1Y
-93.76
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Min Xu
- Full Time Employees
- 58
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Room 606 Hangzhou ZH China
- IPO Date
- May 27, 2025
- Website
- pegbio.com
- Similar Companies
- Business
- PegBio Co., Ltd. is a biopharmaceutical company specializing in the research, development, and commercialization of novel therapeutic agents for chronic diseases, with a focus on GLP-1 based therapies and related metabolic disease programs. The company operates primarily in China, leveraging a pipeline that includes next-generation GLP-1 receptor agonists and multi-receptor agonists designed to address type 2 diabetes, obesity, non-alcoholic fatty liver disease (NAFLD/NASH), and related metabolic conditions. PegBio emphasizes circular RNA (CircRNA)–based approaches and AI-assisted molecular design platforms to accelerate discovery and development, underscoring an integrated strategy that combines biologics with advanced computational methods. Founded in 2008, PegBio maintains its headquarters in Hangzhou, China, and conducts research and development activities as well as clinical programs across the Chinese market, with visibility in Hong Kong-listed market channels under ticker 2565.HK. The company’s product portfolio centers on its PB--series candidates, including PB-119, a GLP-1 receptor agonist intended for type 2 diabetes and obesity treatment; PB-718, positioned for obesity and NASH in later-stage trials; and PB-1902, a GLP-1–based candidate in Phase II trials for obesity and opioid-induced constipation, among other ongoing programs. PegBio also reports pursuit of additional candidates such as PB-2301 and PB-2309, exploring GLP-1/GIP/GCG triple receptor agonism for metabolic indications, and PB-722, which has received FDA orphan drug qualification for congenital hyperinsulinism. The company notes ongoing preclinical evaluation and early clinical validation activities, with emphasis on leveraging AI-assisted design and CircRNA-based protein replacement technologies to enhance GLP-1 receptor activation and broader metabolic pharmacology. PegBio’s geographic footprint centers on China, with regulatory and investor disclosures extending to international markets through the Hong Kong listing and related press releases and regulatory filings. The company outlines its strategic priorities as expanding its metabolic disease pipeline, advancing clinical development for its lead and next-generation GLP-1 programs, pursuing potential partnerships and collaborations to accelerate development and commercialization, and strengthening its translational science capabilities to support first-in-human and later-stage trials. PegBio reports a corporate focus on scientific innovation, regulatory engagement, and strategic alliances to broaden its capabilities in the rapidly evolving landscape of diabetes and metabolic therapeutics.